Get the Stockscreener App
22.73
3.18%
0.70
After Hours:
22.87
0.14
+0.62%
Alumis Inc stock is traded at $22.73, with a volume of 1.59M.
It is up +3.18% in the last 24 hours and down -23.44% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
See More
Previous Close:
$22.03
Open:
$22.49
24h Volume:
1.59M
Relative Volume:
0.54
Market Cap:
$2.89B
Revenue:
$24.05M
Net Income/Loss:
$-243.33M
P/E Ratio:
-7.5757
EPS:
-3.0004
Net Cash Flow:
$-370.18M
1W Performance:
-8.38%
1M Performance:
-23.44%
6M Performance:
+459.85%
1Y Performance:
+213.95%
1-Day Range:
$22.48
$24.30
1-Week Range:
$19.86
$26.40
52-Week Range:
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
22.73 | 2.80B | 24.05M | -243.33M | -370.18M | -3.0004 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | Raymond James | Strong Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-21-26 | Initiated | Chardan Capital Markets | Buy |
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Why Alumis Inc. Shares Are Suddenly Surging - TipRanks
HC Wainwright Brokers Raise Earnings Estimates for Alumis - marketbeat.com
Alumis (NASDAQ:ALMS) Trading 12.1% Higher Following Analyst Upgrade - marketbeat.com
Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST) - theglobeandmail.com
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases - BioSpace
FY2027 Earnings Estimate for Alumis Issued By HC Wainwright - marketbeat.com
Alumis Furthers Its Case In TYK2 Race With Phase III Envudeucitinib Data - insights.citeline.com
Alumis (ALMS): HC Wainwright & Co. Lowers Price Target, Maintains Buy Rating | ALMS Stock News - GuruFocus
Alumis (ALMS) Maintains "Buy" Rating and Price Target by Chardan Capital | ALMS Stock News - GuruFocus
Why is Alumis stock falling Monday? - MSN
Alumis price target raised to $55 from $50 at Oppenheimer - TipRanks
Why Is Alumis Stock Falling Monday?Alumis (NASDAQ:ALMS) - Benzinga
Alumis (NASDAQ:ALMS) Trading Down 11.5% on Analyst Downgrade - marketbeat.com
US Stocks Recap: Is Alumis Incs growth already priced inTrade Exit Report & Verified Short-Term Plans - baoquankhu1.vn
Alumis (NASDAQ:ALMS) Given New $55.00 Price Target at Oppenheimer - MarketBeat
Baird reiterates Alumis stock rating on Phase 3 data strength - investing.com
Guggenheim reiterates Alumis stock rating on psoriasis trial data - investing.com
Leerink reiterates Alumis stock rating on consistent trial data - investing.com
Raymond James reiterates Strong Buy on Alumis stock after trial data - investing.com
Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Envudeucitinib Shows Early, Robust Skin Clearance and Quality of Life Improvements in Phase 3 Plaque Psoriasis Trials by Alumis Inc. 123 - minichart.com.sg
Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating - marketscreener.com
Chardan Capital Reiterates "Buy" Rating for Alumis (NASDAQ:ALMS) - MarketBeat
Stifel reiterates Alumis stock Buy rating after psoriasis data - investing.com
Stifel reiterates Alumis stock Buy rating after psoriasis data By Investing.com - Investing.com Australia
HC Wainwright Cuts Alumis (NASDAQ:ALMS) Price Target to $25.00 - MarketBeat
Alumis stock price target lowered to $25 by H.C. Wainwright on competitive pressures - investing.com
Alumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib - TipRanks
Alumis Inc. Soars On Breakthrough Psoriasis Drug Update - TipRanks
Alumis: Envudeucitinib Shows Robust PASI 90/100 Responses and QoL Gains in Phase 3 ONWARD Trials - TradingView
Phase 3 win positions Alumis (NASDAQ: ALMS) psoriasis pill for 2026 NDA - stocktitan.net
Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout - MarketBeat
Alumis (ALMS) Confronts Potential Regulatory Reassessment with NDA Submission Expected in Second Half of 2026 - Bitget
A Look At Alumis (ALMS) Valuation After ONWARD Phase 3 Psoriasis Data And FDA Filing Plans - simplywall.st
Alumis reports Phase 3 psoriasis trial results for envudeucitinib By Investing.com - Investing.com South Africa
Alumis’ Envudeucitinib Meets Co-Primary Endpoints in ONWARD1 and ONWARD2 Phase 3 Trials - dermatologytimes.com
Alumis reports Phase 3 psoriasis trial results for envudeucitinib - investing.com
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis - manilatimes.net
ALUMIS INC. P3 trial data spotlights TYK2 inhibitor potential in oral psoriasis therapy - tradersunion.com
Alumis Inc. Reports Promising Phase 3 Results for Envudeucitinib in Treating Moderate-to-Severe Plaque Psoriasis at 2026 AAD Annual Meeting - Quiver Quantitative
Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis - Bitget
Psoriasis pill eased itch by Week 2, deepened skin clearance by Week 24 - stocktitan.net
Alumis (ALMS) price target increased by 11.20% to 40.35 - MSN
Taking a Page From Cancer Drugs, Autoimmune Biotech Alumis Aims for Precision Immunology - MedCity News
Alumis Inc. Shares Leap on Drug Trial Buzz - TipRanks
Alumis Inc. (NASDAQ:ALMS) Given Average Recommendation of "Moderate Buy" by Analysts - marketbeat.com
Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets (ALMS) - seekingalpha.com
Why Alumis Inc. Shares Are Surging Today - TipRanks
Alumis (NASDAQ:ALMS) Shares Down 5.8%Here's What Happened - MarketBeat
Why Alumis Inc. Stock Is Suddenly Sinking - TipRanks
The Bull Case For Alumis (ALMS) Could Change Following Envudeucitinib Phase 3 Data And New Equity PlansLearn Why - simplywall.st
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):